Research graph
References from Combined Positive Score and Cost-Effectiveness of Perioperative Pembrolizumab for Head and Neck Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Head and neck squamous cell carcinoma.
10.1038/s41572-020-00224-3 · 2020 · External reference
Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck.
10.1158/1078-0432.ccr-21-0585 · 2021 · External reference
Current progress and future directions of immunotherapy in head and neck squamous cell carcinoma: a narrative review.
10.1001/jamaoto.2024.5254 · 2025 · External reference
Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy.
10.1016/j.ctrv.2023.102644 · 2023 · External reference
Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
10.1016/j.oraloncology.2017.08.008 · 2017 · External reference
Neoadjuvant immunotherapy in non-melanoma skin cancers of the head and neck.
10.1007/s11864-024-01197-1 · 2024 · External reference
Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer.
10.1016/j.ctrv.2025.103018 · 2025 · External reference
Predictive value of combined positive score and tumor proportion score for immunotherapy response in advanced NSCLC.
10.1016/j.jtocrr.2023.100532 · 2023 · External reference
Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer.
10.1056/nejmoa2415434 · 2025 · External reference
Neoadjuvant PD-1 blockade in resectable lung cancer.
10.1056/nejmoa1716078 · 2018 · External reference
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
10.1038/s41591-018-0197-1 · 2018 · External reference
Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine.
10.1001/jama.2016.12195 · 2016 · External reference
Cost-effectiveness of perioperative nivolumab for stage III Non-small-cell lung cancer: a perspective from the United States.
10.1016/j.clinthera.2025.07.002 · 2025 · External reference
Improved curve fits to summary survival data: application to economic evaluation of health technologies.
10.1186/1471-2288-11-139 · 2011 · External reference
Conditional relative survival in head and neck squamous cell carcinoma: permanent excess mortality risk for long-term survivors.
10.1002/hed.21369 · 2010 · External reference
Decreased cancer-independent life expectancy in the head and neck cancer population.
10.1002/hed.24850 · 2017 · External reference
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
10.1080/13696998.2020.1715414 · 2020 · External reference
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
10.1016/s0140-6736(19)32591-7 · 2019 · External reference
Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
10.1056/nejmoa1602252 · 2016 · External reference
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
10.1016/s0140-6736(25)01850-1 · 2026 · External reference
Optimized PD-L1 scoring of gastric cancer.
10.1007/s10120-021-01195-4 · 2021 · External reference
Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta-analysis and cost-effectiveness analysis.
10.1001/jamanetworkopen.2021.8065 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.15620/cdc/174591
10.15620/cdc/174591 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
